The need for novel therapeutic agents in myeloproliferative neoplasms

In this video, Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines novel therapeutic approaches for the treatment of patients with myeloproliferative neoplasms (MPNs). The development of novel therapeutic agents in this field is urgently required due to the variety of MPN subtypes. Dr Pemmaraju highlights the promise of immunotherapies such as CAR-Ts and NK-cells, as well as other novel approaches, including those that target the CALR mutation. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.